OBJECTIVE: Recently, an iMRI-guided technique for implanting DBS electrodes without MER was developed at our center. Here we report the clinical outcomes of PD patients undergoing STN DBS surgery using this surgical approach. METHODS: Consecutive PD patients undergoing bilateral STN DBS using this method were prospectively studied. Severity of PD was determined using the UPDRS scores, Hoehn and Yahr staging score, stand-sit-walk testing, and the dyskinesia rating scale. The primary outcome measure was the change in UPDRS III off medication score at 6 months. DBS stimulation parameters, adverse events, levodopa equivalent daily dose (LEDD), and DBS lead locations were also recorded. Seventeen advanced PD patients (9M/8F) were enrolled from 2007 to 2009. RESULTS: The mean UPDRS III off medication score improved from 44.5 to 22.5 (49.4%) at 6 months (p=0.001). Other secondary outcome measures (UPDRS II, III on medication, and IV) significantly improved as well (p<0.01). LEDD decreased by an average of 24.7% (p=0.003). Average stimulation parameters were: 2.9V, 66.4μs, 154Hz. CONCLUSION: This pilot study demonstrates that STN DBS leads placed using the iMRI-guided method results in significantly improved outcomes in PD symptoms, and these outcomes are similar to what has been reported using traditional frame-based, MER-guided stereotactic methods.
OBJECTIVE: Recently, an iMRI-guided technique for implanting DBS electrodes without MER was developed at our center. Here we report the clinical outcomes of PDpatients undergoing STN DBS surgery using this surgical approach. METHODS: Consecutive PDpatients undergoing bilateral STN DBS using this method were prospectively studied. Severity of PD was determined using the UPDRS scores, Hoehn and Yahr staging score, stand-sit-walk testing, and the dyskinesia rating scale. The primary outcome measure was the change in UPDRS III off medication score at 6 months. DBS stimulation parameters, adverse events, levodopa equivalent daily dose (LEDD), and DBS lead locations were also recorded. Seventeen advanced PDpatients (9M/8F) were enrolled from 2007 to 2009. RESULTS: The mean UPDRS III off medication score improved from 44.5 to 22.5 (49.4%) at 6 months (p=0.001). Other secondary outcome measures (UPDRS II, III on medication, and IV) significantly improved as well (p<0.01). LEDD decreased by an average of 24.7% (p=0.003). Average stimulation parameters were: 2.9V, 66.4μs, 154Hz. CONCLUSION: This pilot study demonstrates that STN DBS leads placed using the iMRI-guided method results in significantly improved outcomes in PD symptoms, and these outcomes are similar to what has been reported using traditional frame-based, MER-guided stereotactic methods.
Authors: M C Rodriguez-Oroz; M Rodriguez; J Guridi; K Mewes; V Chockkman; J Vitek; M R DeLong; J A Obeso Journal: Brain Date: 2001-09 Impact factor: 13.501
Authors: F Godinho; S Thobois; M Magnin; M Guenot; G Polo; I Benatru; J Xie; A Salvetti; L Garcia-Larrea; E Broussolle; P Mertens Journal: J Neurol Date: 2006-06-20 Impact factor: 4.849
Authors: Donald C Shields; Alessandra Gorgulho; Eric Behnke; Dennis Malkasian; Antonio A F DeSalles Journal: J Neurosurg Date: 2007-07 Impact factor: 5.115
Authors: Elena Moro; Andres M Lozano; Pierre Pollak; Yves Agid; Stig Rehncrona; Jens Volkmann; Jaime Kulisevsky; Jose A Obeso; Alberto Albanese; Marwan I Hariz; Niall P Quinn; Jans D Speelman; Alim L Benabid; Valerie Fraix; Alexandre Mendes; Marie-Laure Welter; Jean-Luc Houeto; Philippe Cornu; Didier Dormont; Annalena L Tornqvist; Ron Ekberg; Alfons Schnitzler; Lars Timmermann; Lars Wojtecki; Andres Gironell; Maria C Rodriguez-Oroz; Jorge Guridi; Anna R Bentivoglio; Maria F Contarino; Luigi Romito; Massimo Scerrati; Marc Janssens; Anthony E Lang Journal: Mov Disord Date: 2010-04-15 Impact factor: 10.338
Authors: T M Moriarty; A Quinones-Hinojosa; P S Larson; E Alexander; P L Gleason; R B Schwartz; F A Jolesz; P M Black Journal: Neurosurgery Date: 2000-11 Impact factor: 4.654
Authors: Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda Journal: N Engl J Med Date: 2010-06-03 Impact factor: 91.245
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272
Authors: Philip A Starr; Alastair J Martin; Jill L Ostrem; Pekka Talke; Nadja Levesque; Paul S Larson Journal: J Neurosurg Date: 2010-03 Impact factor: 5.115
Authors: Marc C Mabray; Sanjit Datta; Prasheel V Lillaney; Teri Moore; Sonja Gehrisch; Jason F Talbott; Michael R Levitt; Basavaraj V Ghodke; Paul S Larson; Daniel L Cooke Journal: J Neurointerv Surg Date: 2015-06-05 Impact factor: 5.836
Authors: Matthew T Silvestrini; Dali Yin; Alastair J Martin; Valerie G Coppes; Preeti Mann; Paul S Larson; Philip A Starr; Xianmin Zeng; Nalin Gupta; S S Panter; Tejal A Desai; Daniel A Lim Journal: Mol Ther Date: 2014-08-20 Impact factor: 11.454
Authors: Hooman Azmi; Fiona Gupta; Mario Vukic; Jason Kreitner; Elizabeth Kera; Gregory Nicola; Sean Pierce; David Panush; Randy Cohen Journal: Surg Neurol Int Date: 2016-08-02